Competing interests
GMC serves on the board of directors of Satellite Healthcare, a not-for-profit dialysis provider. His institution (Stanford University) has received grant funding from clinical trial sponsor CSL Behring. GMC has chaired or co-chaired clinical trial steering committees with Akebia, AstraZeneca, CSL Behring, Sanifit and Vertex. He has also served as an advisor for Alexion, Applaud, Ardelyx, CalciMedica, Calico, CloudCath, Durect, Eliaz Therapeutics, Miromatrix, Outset, Renibus and Unicycive. He has chaired or served on data safety monitoring committees for clinical trials sponsored by Bayer, Mineralys and ReCor. AMC, MH, RC, JM and PT are employees of and hold stock in CSL Behring. EV is an employee of CSL Limited. GMF has received research grants from NIH, Bayer, BMS, Novartis, Daxol, Merck, Cytokinetics, and CSL Behring, and has served as a consultant for Novartis, BMS, Cytokinetics, Innolife, Boehringer Ingelheim, Abbott, Sanofi, Regeneron, Myovant, Sequana, Windtree Therapeutics, and Whitewell, and serves on clinical endpoint/data safety monitoring boards for Merck, Medtronic, EBR Systems, Rocket Pharma, V-Wave, and LivaNova. BF is employed by CSL Behring. DMC reports consulting history for Eli Lilly/Boehringer Ingelheim, AstraZeneca, Arena Pharmaceuticals (DSMB), Gilead, Novo Nordisk, GSK, Medtronic, Merck, CSL Behring, Zogenix, Renalytics, and LG Chemical. has received patent or royalties for review writing/editorials from UpToDate.com in collaboration with Novo Nordisk, Amgen, and Boehringer Ingelheim/Eli Lilly. CMG has received research and consulting support from CSL Behring. SGG has received research grant support (e.g., steering committee and data and safety monitoring committee) and speaker/consulting honoraria (e.g., advisory board) from CSL Behring, Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CYTE Ltd., Daiichi Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, Idorsia, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma and salary support/honoraria from the Heart Failure Society of Canada, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Clinical Research Coordinating Centre, Duke Clinical Research Institute, Jewish General Hospital\CIUSSS. Centre-Ouest-de-l'Ile-de-Montreal, New York University Clinical Coordinating Center, PERFUSE Institute, Peter Munk Cardiac Center Clinical Trials and Translation Unit, Ted Rogers Heart Center, and TIMI Research Group (Brigham Health). MJ is supported by CSL Behring. AL is supported by CSL Behring. RM has received institutional research funding from Abbott, Abiomed, Affluent Medical, Alleviant Medical, Amgen, AM Pharma, Arena, AstraZeneca, AtriCure, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CeloNova, CERC, Chiesi, Cleerly Health, Concept Medical, Cytosorbents, Daiichi Sankyo, Duke, Element Science, Essential Medical, Faraday, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere, Medtelligence, Medtronic, MJH Healthcare, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi Cardia, PLx Pharma, Population Health Research Institute, Protembis, RecCor Medical, RenalPro, RM Global, Sanofi, Shockwave and Vivasure, and Zoll. She has received personal fees from Affluent Medical, Boehringer Ingelheim, Cardiovascular Research Foundation (CRF), Cordis, Daiichi Sankyo Brazil, ER Squibb-Sands, Esperion Sciences/Innovative BioPharma, Europe Group/Boston Scientific, Gaffney Events, Educational Trust, Henry Ford Health Cardiology, Ionis Pharmaceuticals, Lilly and Company, Medcon International, Novartis, Novo Nordisk, Peer View Medical Education Institute, Terumo Europe NV, Vector, VoxMedia, WebMD, IQVIA, Radcliffe, and TARSUS Cardiology. She has received personal fees from the American Medical Association. JAMA CardiologyACC (BOT member, SC member CTR program) and holds less than 1% shares in Elixir Medical, Stel. PS has received research support from AstraZeneca and Bayer. He was a SAB member for Baxter, FMC, Boehinger Mannheim, CSL, Alexion, GSK and lnvizius. DCW has received honoraria/consultant fees and/or speaking fees from AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Eledon, Galderma, GSK, Gilead, Merck, Pharmacosmos, ProKidney, Tricida and Vifor. PMR has received institutional research grant support from Kowa, Novartis, Amarin, Pfizer, Esperion, Novo Nordisk and NHLBI. In the past 5 years he has served as a consultant for Novartis, Flame, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Civi Biopharm, GSK, SOCAR, Novo Nordisk, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer Ingelheim, RTI, Zomagen, Cytokinetics, Horizon Therapeutics, and Cardio Therapeutics. He has minority interests in Uppton, Bitterroot Bio, and Angiowave, and has received compensation for activities on the Peter Munk Advisory Board (University of Toronto), Leducq Foundation, Paris FR, and Baim Institute (Boston, MA). KWM receives institutional and consulting funding from CSLB. MW receives research support from CSL through his affiliated institution, Duke Clinical Research Institute, for his current study.
